Supplementary Figure 8
Cytokine production by multiplex assay in plasma from patients F5-12 and F5-14 to study the potential development of a cytokine storm.

UCLA F5-12 (5 Days Post-Infusion)  UCLA F5-14 (4 Days Post-Infusion)

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>UCLA F5-12</th>
<th>UCLA F5-14</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFN-γ</td>
<td>0</td>
<td>284.3</td>
</tr>
<tr>
<td>TNF-α</td>
<td>0</td>
<td>11.6</td>
</tr>
<tr>
<td>GMP SCR</td>
<td>8.4</td>
<td>60.6</td>
</tr>
<tr>
<td>IL-6</td>
<td>111</td>
<td>372.2</td>
</tr>
<tr>
<td>IL-10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NCI CAR SAE Case (4 hrs Post-Infusion)  London Anti-CD28, Avg of 6 patients (4 hrs Post-Infusion)

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>NCI SAE Case</th>
<th>London Anti-CD28</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFN-γ</td>
<td>11,456</td>
<td>5000</td>
</tr>
<tr>
<td>TNF-α</td>
<td>10,191</td>
<td>4673</td>
</tr>
<tr>
<td>GMP SCR</td>
<td>34,467</td>
<td>Data not available</td>
</tr>
<tr>
<td>IL-6</td>
<td>274</td>
<td>3500</td>
</tr>
<tr>
<td>IL-10</td>
<td></td>
<td>2000</td>
</tr>
</tbody>
</table>